Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195689 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00195689 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 400 participants.
The verdict
NCT00195689, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
Interventions
- BIOLOGICAL Human anti-TNF monoclonal antibody/adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195689
The ClinicalTrials.gov registry entry for NCT00195689 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Human anti-TNF monoclonal antibody/adalimumab is the first listed.
NCT00195689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195689 about?
NCT00195689 is a clinical study titled "Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis". The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis
What is the current status of trial NCT00195689?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2003-08.
What interventions are being tested in trial NCT00195689?
The interventions under investigation include: Human anti-TNF monoclonal antibody/adalimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00195689?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.